NewsBenzingaTeva Pharmaceutical Indus Raises FY2026 Adj EPS Guidance from $1.91-$2.11 to $1.92-$2.11 vs $1.98 Est; Raises FY2026 Sales Guidance from $16.500B-$16.850B to $16.700B-$17.000B vs $16.651B Est Teva Pharmaceutical Indus Raises FY2026 Adj EPS Guidance from $1.91-$2.11 to $1.92-$2.11 vs $1.98 Est; Raises FY2026 Sales Guidance from $16.500B-$16.850B to $16.700B-$17.000B vs $16.651B Est Benzinga 2026.11.03 12:08 (GMT+0) Open on Benzinga Other news Musk: Expects SpaceX to sell no compute to OpenAI Wall Street prepares for Anthropic IPO frenzy, despite broader AI stock slump Iron Mountain Stock: Is Wall Street Bullish or Bearish? HTX DeepThink: Leverage Flush-Out May Not Mark a Bottom; Weak Spot Demand Could Keep BTC Under Pressure What Wall Street analysts are now saying after Nvidia’s beat-and-raise quarter More Than a Swap: PancakeSwap Rebrands as Pancake Ahead of Mobile App Launch
HTX DeepThink: Leverage Flush-Out May Not Mark a Bottom; Weak Spot Demand Could Keep BTC Under Pressure